Cell. 2020 Apr 2;181(1):15-18. doi: 10.1016/j.cell.2020.03.016.
Developing a therapy for patients in need of treatment is a resource-consuming, labor-intensive process that's fraught with challenges. Pharmaceutical companies have long been the engines driving generation of new medicines. Lara Szewczak spoke with Daria Hazuda, Vice President of Infectious Disease Discovery at Merck & Co. and CSO of MRL Cambridge Exploratory Science Center, and Morris Birnbaum, Senior Vice President and Chief Scientific Officer of Pfizer's Internal Medicine Research Unit about their hopes for how Large Pharma will evolve to address current and future medical needs of complex patient populations. Excerpts from this conversation are presented below, and the full conversation is available with the article online. Editor's note: Due to technical difficulties on the phone call, some text was subsequently revised by D.H. for clarity.
为有治疗需求的患者开发疗法是一个资源密集型、劳动密集型的过程,充满了挑战。制药公司长期以来一直是推动新药研发的引擎。Lara Szewczak 采访了默克公司传染病发现副总裁、MRL 剑桥探索科学中心首席科学官 Daria Hazuda 和辉瑞公司内科研究部高级副总裁兼首席科学官 Morris Birnbaum,探讨大型制药公司将如何发展以满足复杂患者群体的当前和未来的医疗需求。此次对话的节选如下,完整对话可在网上文章中查看。编辑注:由于电话通话中的技术困难,随后由 D.H. 对一些文本进行了修订,以确保清晰。